Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Margaret M. Woo"'
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The study aimed to characterize the population pharmacokinetics of panobinostat, a pan-deacetylase inhibitor that has demonstrated efficacy in combination with bortezomib and dexamethasone in patients with multiple myeloma. Methods A nonlinea
Autor:
Asuka Yamamoto, Taro Amagasaki, Kazuto Natsume, Margaret M. Woo, Yoichiro Ogama, Tomoko Mineyama, Naomi Shimada
Publikováno v:
International Journal of Hematology. 97:351-359
Ruxolitinib (INC424), a potent and selective oral Janus kinase 1 and 2 inhibitor, was recently approved by the US food and drug administration for the treatment of intermediate or high-risk myelofibrosis. The safety, tolerability, and pharmacokinetic
Autor:
Margaret Squier, Brian Gadbaw, Monica M. Mita, Margaret M. Woo, Sofia Paul, Sunil Sharma, H. Miles Prince, Joachim Beck
Publikováno v:
Investigational New Drugs. 31:974-985
Purpose Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study wa
Publikováno v:
Cancer Chemotherapy and Pharmacology. 64:867-875
To determine the inhibitory potency of letrozole and its main human metabolite, 4,4'-methanol-bisbenzonitrile, on the activities of eight cytochrome P450 (CYP) enzymes.Letrozole and its metabolite were incubated with human liver microsomes (HLMs) (or
Autor:
Lihui Zhao, Natasha B. Leighl, Ronald Feld, Frances A. Shepherd, Thomas Hengelage, Lucien Gazi, Asha Nayak, Maria Grazia Porro, J. Thaddeus Beck, Margaret M. Woo
Publikováno v:
Cancer chemotherapy and pharmacology. 72(4)
Panobinostat is a potent oral pan-deacetylase inhibitor with promising clinical activity in hematologic malignancies. Panobinostat was shown to inhibit CYP2D6 activity in vitro; thus understanding the magnitude of the potential clinical inhibition of
Autor:
Angela Liu, Daniel J. DeAngelo, Thomas Kindler, Katie Parker, Margaret M. Woo, Jeffrey W. Scott, Henry Miles Prince, Oliver G. Ottmann, Kapil N. Bhalla, Tamas Fischer, Kaushal Mishra, Andrew Spencer, Francis J. Giles, Peter Atadja
Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d1bdb7fcc1c3c660aa8c2b3f2dfb63
http://hdl.handle.net/10379/11111
http://hdl.handle.net/10379/11111
Publikováno v:
Cancer chemotherapy and pharmacology. 70(4)
Elucidating the metabolic profile of anticancer agent panobinostat is essential during drug development. Disposition, metabolism, and excretion profiles were characterized using trace radiolabeled (14)C-panobinostat in four patients with advanced can
Autor:
Geoffrey I. Shapiro, Lionel D. Lewis, Richard G. Frank, Lucien Gazi, Margaret M. Woo, Maria Grazia Porro, Lily Zhao, Thomas Hengelage, Uday B. Dandamudi
Panobinostat is a novel oral pan-deacetylase inhibitor with promising anti-cancer activity. The study aimed to determine the influence of food on the oral bioavailability of panobinostat.This multicenter study consisted of a randomized, three-way cro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df920c200edfd5125044c093aa261b09
https://europepmc.org/articles/PMC4491112/
https://europepmc.org/articles/PMC4491112/
Autor:
Paul Hamberg, Lin Chi Chen, Diane A.J. van der Biessen, Thomas Hengelage, Wenkui Li, Sunil Sharma, Lily Zhao, Jaap Verweij, Maja J.A. de Jonge, Margaret M. Woo, Maria Grazia Porro
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat. Methods Patients received a single panobinostat oral dose on
Autor:
Aseem Anand, Erika Tanaka, Bryan Y. Wong, Andy Dzik-Jurasz, Jing Hu, Wei Yang, Robert W. Ross, Margaret M. Woo, Howard I. Scher, Dana E. Rathkopf
Publikováno v:
Cancer chemotherapy and pharmacology. 66(1)
Histone deacetylase inhibitors have demonstrated anticancer activity against a range of tumors. We aimed to define the maximum tolerated dose, toxicity, activity, and pharmacokinetics of oral panobinostat, a pan-deacetylase inhibitor, alone and in co